Geographical differences in the use of oral corticosteroids in patients with severe asthma in Spain: heat map based on existing databases analyses

Abstract

Background Although there are currently alternative treatments to the long-term use of oral corticosteroids (OCS) in severe asthma, recent studies show excessive use depending on geography and differences in medical practice. The objective of the study was to describe the differences in OCS use for severe asthma across the Spanish geography. Methods This is a real-world study using existing databases (year 2019): longitudinal patient database (EMR), based on electronic medical records, and database of pharmacological consumption (Sell-in) in basic healthcare areas. With EMR, the percentage of OCS prescriptions corresponding to patients with severe asthma (ICD-9 “asthma” and prescription of biological treatment and/or high dose of inhaled corticosteroids/long-acting inhaled β2 agonists) was calculated. This percentage was transferred to the OCS consumption of each basic healthcare area as reported in the Sell-in database and a national heat map was created. The estimation of OCS use in patients with severe asthma per 100,000 inhabitants for each region was calculated by grouping basic healthcare areas and the mean OCS use per patient for different regions in Spain was also estimated. Results Patients with severe asthma in Spain were mostly female (69.6%), with a mean age (SD) of 57.6 years (18.01). Median time (Pc25–Pc75) since asthma diagnosis was 83.1 months (34.65–131.56). Of all patients with OCS prescriptions in 2019 identified in EMR, 4.4% corresponded to patients with severe asthma. Regions with the highest OCS use were Asturias, Andalucía, and Galicia, whereas those with the lowest use were Navarra, Baleares, Madrid and País Vasco. The mean OCS use per patient with severe asthma in 2019 throughout Spain was 1099.85 mg per patient, ranging from 782.99 mg in Navarra to 1432.64 in Asturias. Conclusions There are geographical differences between Spanish regions with respect to the use of OCS in patients with severe asthma. The national mean consumption of OCS per patient with severe asthma and year is above the limits that indicate good asthma control.

Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: ORBE II study

“…A real-world study in Spain estimated the 1-year cumulative OCS dose in 2019 to be more than 1 g per SA patient [ 63 ], showing that there is still high OCS overuse even with the current availability of alternative therapeutic approaches such as biologics. In this sense, a recent Spanish multidisciplinary consensus highlights the need to monitor the cumulative OCS dose, and strongly recommends that patients receiving a cumulative OCS dose of ≥ 0.5 g per year should be provided with alternative therapeutic options [ 7 ].…”

Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases

“…Thus, biologics are recommended before chronic SGC in uncontrolled patients (72). Despite the proven reduction in exacerbation rates and SGC-sparing effects in real-life studies (73,74), biologics are still underprescribed in most regions in Spain (75,76).…”

Using Convolutional Neural Network for Detection of Face Mask

“…Confusion matrix and heat map are used to demonstrate the degree of the accuracy of model [13]. Each column of the confusion matrix represents the prediction category, and the total number of each column represents the number of data predicted for that category.…”